MS
MCRB icon

Maven Securities’s Seres Therapeutics MCRB Stock Holding History

Maven Securities’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-57,725
Closed -$3.96M – 1175
2022
Q2 		$3.96M Buy
+57,725
New +$4.97M 0.12% 132
2019
Q4 		– Sell
-5,000
Closed -$395K – 392
2019
Q3 		$395K Sell
5,000
-3,252
-39% -$215K 0.12% 153
2019
Q2 		$526K Buy
+8,252
New +$783K 0.35% 56

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Maven Securities's MCRB Position: Q3 2022 in Review

Maven Securities sold out of Seres Therapeutics (MCRB) in Q3 2022, closing a stake of 57,725 shares — an estimated $3.96M sold.

Maven Securities first reported a position in MCRB in Q2 2019 and held it in 3 quarters. The position peaked at $3.96M in Q2 2022. 119 funds tracked by Wall St. Rank hold MCRB as of Q3 2022.

  • Maven Securities reported no remaining Seres Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Maven Securities sold 57,725 Seres Therapeutics shares in Q3 2022, an estimated $3.96M.
  • Maven Securities first reported a position in Seres Therapeutics in Q2 2019 and held it in 3 quarters.
  • Maven Securities's Seres Therapeutics position peaked at $3.96M in Q2 2022.
  • 119 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2022.

Based on Maven Securities's 13F filing for Q3 2022, filed 14 Nov 2022.